Lymphatic metastasis is an important prognostic factor in malignancies. Most tumors are classified according to the TNM staging system, and treatment and prognosis are modified when lymph node metastases are present. Lymph node staging by physical examination is not accurate in discriminating metastatic from benign lymph nodes. Even in superficial areas such as the cervical and inguinal regions, a physical evaluation of lymph nodes cannot reliably detect metastases (1,2). The best method and current reference standard for staging lymph node metastases is histopathologic examination. However, this is an invasive surgical procedure in which complications and morbidity may occur. Noninvasive imaging tools, such as computed tomography and magnetic resonance imaging (MRI), are available as methods to enhance the diagnostic evaluation of lymph nodes. However, conventional MRI and computed tomography mainly evaluate the size of lymph nodes. Although it had been assumed that the use of lymph node characteristics, such as homogeneity, margins, and shape, as diagnostic criteria would improve the ability of MRI to discriminate between benign and metastatic lymph nodes, several studies (3) (4) (5) showed that the use of these morphological characteristics did not improve the accuracy of conventional MRI.
Lymphatic metastasis is an important prognostic factor in malignancies. Most tumors are classified according to the TNM staging system, and treatment and prognosis are modified when lymph node metastases are present. Lymph node staging by physical examination is not accurate in discriminating metastatic from benign lymph nodes. Even in superficial areas such as the cervical and inguinal regions, a physical evaluation of lymph nodes cannot reliably detect metastases (1, 2) . The best method and current reference standard for staging lymph node metastases is histopathologic examination. However, this is an invasive surgical procedure in which complications and morbidity may occur. Noninvasive imaging tools, such as computed tomography and magnetic resonance imaging (MRI), are available as methods to enhance the diagnostic evaluation of lymph nodes. However, conventional MRI and computed tomography mainly evaluate the size of lymph nodes. Although it had been assumed that the use of lymph node characteristics, such as homogeneity, margins, and shape, as diagnostic criteria would improve the ability of MRI to discriminate between benign and metastatic lymph nodes, several studies (3) (4) (5) showed that the use of these morphological characteristics did not improve the accuracy of conventional MRI. 
Background
Gadolinium-based contrast agents are used with magnetic resonance imaging (MRI) to highlight tumor vascularity in organs. They are also widely used for primary tumor visualization. We conducted a systematic review and meta-analysis of the existing evidence of the accuracy of gadolinium-enhanced MRI for staging lymph node metastases.
Methods
We systematically searched the MEDLINE, Cochrane, CANCERLIT, and EMBASE databases for studies published in English or German from January 1, 1988 , to January 1, 2008 , that assessed the diagnostic accuracy of gadolinium-enhanced MRI in the evaluation of lymphatic metastases compared with histopathologic examination as the reference test. Based on a priori-defined clinical considerations, we studied three subgroups of studies: those that used a single malignancy criterion and those that used multiple malignancy criteria with or without contrast highlighting. Summaries of MRI sensitivity and specificity for detecting lymph node metastases were calculated using a bivariate regression model. All statistical tests were two-sided.
Results
The literature search yielded 43 full-text papers that were considered for inclusion in the meta-analysis. We performed quantitative pooled analyses on the 32 studies that provided data on patient-level diagnosis. The weighted estimates of sensitivity and specificity for all studies combined were 0.72 (95% confidence interval [CI] = 0.66 to 0.79) and 0.87 (95% CI = 0.82 to 0.91). Estimates of sensitivity and specificity were essentially unchanged for studies that used a single malignancy criterion (0.71 [95% CI = 0.61 to 0.79] and 0.88 [95% CI = 0.80 to 0.93], respectively; n = 11 studies) or multiple malignancy criteria without contrast enhancement (0.70 [95% CI = 0.58 to 0.79] and 0.86 [95% CI = 0.68 to 0.94], respectively; n = 6 studies). The sensitivity increased to 0.84 (95% CI = 0.70 to 0.92), with a specificity of 0.82 (95% CI = 0.72 to 0.89) for the nine studies that incorporated contrast enhancement in their multiple malignancy criteria. Six studies did not define the malignancy criteria they used.
Contrast-enhanced MRI has been proposed as a tool for improving the diagnostic accuracy of nodal metastases detection (6) . One of the contrast agents used with enhanced MRI is ultrasmall superparamagnetic iron oxide (USPIO) particles. A meta-analysis of the diagnostic precision of USPIO-enhanced MRI for detection of lymph node metastasis showed an overall sensitivity of 0.88 (95% confidence interval [CI] = 0.85 to 0.91) and specificity of 0.96 (95% CI = 0.95 to 0.97) (6) . However, this staging method also has a number of disadvantages, including the need for slow infusion of the contrast agent 24 hours before imaging to minimize hypersensitivity-related side effects (7, 8) . Moreover, interpretation of the magnetic resonance images is not a trivial task (9) . Consequently, the USPIO contrast agent has not yet been registered at the European Medicines Agency nor has it been approved by the US Food and Drug Administration.
It is thought that the lymph node prepares for metastatic cell implantation by reorganizing lymphatic and vascular structures and, as a consequence, new blood vessels develop within and around lymph nodes (10) . The administration of an intravenous contrast agent, such as gadolinium, can reveal these surrounding blood vessels and demonstrate additional morphological characteristics of tumor tissue (11) (12) (13) . Although gadolinium should be used with care in patients with nephropathy, it is generally accepted as a safe contrast agent when compared with USPIO (14, 15) . As such, it has been used extensively to visualize a variety of tumors with increased angiogenesis and blood flow [eg, (16) ].
The number of studies that have evaluated the accuracy of gadolinium-enhanced MRI to detect nodal metastases compared with that of histopathologic examination has increased sharply in the last decade to more than 30 (3, 4) . However, to our knowledge, a systematic review of all of these studies has not yet been undertaken. The purpose of this study was to quantitatively summarize, by means of a meta-analysis, all existing evidence in the literature on the diagnostic accuracy of MRI with intravenously administered gadolinium to detect metastatic lymph nodes in any cancer.
Methods

Search Strategy
We performed a comprehensive search of English-and Germanlanguage literature to identify articles that examined the diagnostic accuracy of gadolinium-enhanced MRI (as an index test) in the evaluation of lymph node metastases using histopathology as the reference standard. We searched the MEDLINE, Cochrane, CANCERLIT, and EMBASE databases for studies published from January 1, 1988 , to January 1, 2008, with the medical subject headings (MeSH) terms "lymph nodes" OR "lymphatic metastasis" and with "lymph node" or "lymph nodes" and "gado* OR gd" as text words. We explicitly included no terms related to the type of cancer because our aim was to analyze the accuracy of gadolinium to detect lymphatic metastases regardless of the location or type of the primary tumor. We identified additional references by cross-checking bibliographies of retrieved full-text papers.
Study Selection and Data Extraction
We included studies that met all of the following inclusion criteria: 1) a minimal sample size of 10 patients with histologically proven cONteXt AND cAVeAtS
Prior knowledge
Magnetic resonance imaging with gadolinium-based contrast agents is widely used to visualize primary tumors and to highlight tumor vascularity.
Study design
A systematic review and meta-analysis of studies that assessed the diagnostic accuracy of gadolinium-enhanced magnetic resonance imaging in the evaluation of lymphatic metastases compared with histopathologic examination as the reference test.
Contribution
The overall accuracy of gadolinium-enhanced magnetic resonance imaging for the detection of nodal metastases is moderate. Incorporating contrast enhancement in the malignancy criteria substantially improves the accuracy of this diagnostic test.
Implications
Contrast highlighting of lymph nodes should be included as a malignancy criterion when gadolinium contrast agent is used for primary tumor visualization.
Limitations
Not all of the included studies reported diagnostic study quality, which precluded formal analyses based on the quality assessment items. A regression test for small-study effects was statistically significant, indicating that the retrieved studies had results that may not be representative of the full range of evidence that has been produced (publication bias). In the overall analyses of the diagnostic accuracy of gadolinium-enhanced magnetic resonance imaging for the detection of lymph node metastases, studies were pooled without regard to the primary tumor site.
From the Editors primary carcinoma; 2) evaluation of gadolinium-enhanced MRI compared with histopathology of lymph nodes obtained by surgery, autopsy, or biopsy as the reference standard; and 3) sufficient data to (re)construct a 2 × 2 contingency table such that the cells in the table could be labeled as true positive, false positive, true negative, and false negative. We excluded studies that included healthy volunteers only or patients with nonlymphatic metastases, and studies having possible overlap with the selected studies (ie, studies from the same study group, institution, and period of inclusion).
The selection of studies for this meta-analysis was done in two consecutive phases: assessment of the title and abstract by one reviewer (W. M. Klerkx) and assessment of the full article by two independent reviewers (W. M. Klerkx and W. B. Veldhuis). Discrepancies between the two reviewers were resolved having additional reviewers (P. H. M. Peeters and/or K. G. M. Moons) assess the full article, and the decision about whether to include the article was made by consensus. The two original reviewers independently extracted relevant data from the articles that were selected for inclusion in the meta-analysis by using a standard score form that included the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) criteria (17) .
For the meta-analysis of diagnostic accuracy data, the two reviewers extracted the numbers of true positives, false positives, true negatives, and false negatives from each study. When diagnostic data in the article were only presented at the level of the lymph node region, site, or tumor diagnosis, we requested patient-level data from the authors of the study. In addition to the QUADAS criteria and the contents of the 2 × 2 table, we also recorded following information: overall study characteristics (including the first author, country, language, and date of publication); patient characteristics (including mean age at time of study inclusion, site of the primary tumor, stage of disease, and sex ratio); and characteristics regarding the MRI scan and evaluation (including magnetic field strength; type, dosage, and administration route of the gadolinium contrast agent; the number of reviewers and whether they were blinded to each others results; the type and number of malignancy criteria; and whether the malignancy criteria were defined before or after analysis). We classified malignancy criteria according to the definition that was used to indicate a metastatic lymph node. Subsequently, we grouped the studies according to their malignancy criteria as follows: Studies that had a single malignancy criterion (ie, studies that used the size of the lymph node to indicate a metastasis), studies that had multiple malignancy criteria but excluded gadolinium enhancement in the malignancy criteria, and studies that evaluated lymph node metastases by multiple malignancy criteria including gadolinium enhancement. We also documented reference standard characteristics, including the method of lymph node harvesting, histopathologic staining, and sectioning of the histological material.
When raw data were presented in 3 × 3 or 4 × 4 tables (eg, when the lymph node stage was defined as N0 [no metastases], N1 [metastasis in one lymph node], N2 [metastases in two lymph nodes], or N3 [metastases in distant lymphatic draining region]), we reconstructed 2 × 2 tables by considering N1 and higher stages as metastasis-positive lymph nodes and N0 as metastasis-negative lymph nodes, as has been done in most other individual studies [eg, (18) ]. Two articles (3, 19) presented raw data for several malignancy criteria. We consistently used the data with the highest sensitivity and performed a sensitivity analysis in which we used the data with the lowest sensitivity instead of the data with the highest sensitivity.
Data Preparation and Statistical Analysis
We used forest plots to assess the precision with which sensitivity and specificity had been measured in each study and to evaluate heterogeneity across studies. We then used a bivariate randomeffects approach to obtain weighted overall estimates of the sensitivity and specificity of gadolinium-enhanced MRI in detecting lymph node metastasis (20, 21) . This approach assumes a bivariate distribution for the logit-transformed values of paired sensitivity and specificity. Overall sensitivity and specificity and their 95% confidence intervals were calculated based on the binominal distributions of the true positives and true negatives. Besides accounting for study size, the bivariate model adjusts for the negative correlation between the sensitivity and the specificity of the index test. Univariate models analyze the sensitivity and specificity independently and do not take into account that between-study differences may be because of threshold differences in malignancy criteria. A bivariate approach can model this dependency explicitly. An additional advantage of using the bivariate model is that the bivariate nature of the original data can be maintained throughout the analysis, allowing the generation of summary estimates of sensitivity and specificity. A summary receiver operating characteristic curve was constructed as a way to summarize the true-and falsepositive rates from different diagnostic studies.
To formally quantify the extent of between-study variation (ie, heterogeneity), we calculated the Q and I 2 statistics (22) . The I 2 statistic describes the proportion of total variation in study estimates that is because of heterogeneity, which ideally would be 0%. We anticipated that there would be substantial clinical heterogeneity and between-study variation in reported pairs of sensitivity and specificity, particularly because of differences how malignancy was defined on the magnetic resonance images. Hence, we estimated the overall accuracy of the index test across the three a priori-defined subgroups of studies based on the number and type of criteria used to determine that the lymph nodes shown on the magnetic resonance images were malignant (ie, studies that used a single criterion, studies that used multiple criteria without incorporating contrast highlighting, and studies that used multiple criteria including contrast highlighting). These three subgroups were chosen because they would allow clinicians to determine whether or not to take contrast enhancement into account as a malignancy criterion.
In addition to this primary subgroup analysis, we also investigated the effect of potential sources of heterogeneity on the diagnostic accuracy of gadolinium-enhanced MRI by including covariates in the bivariate model. Because the number of studies was too small to perform such analyses without sufficient protection for type I errors, we tested the covariates one at a time and, thus, consider this to be an exploratory analysis and the results as hypothesis generating. The covariates included in this analysis were lymph node region (upper abdomen, regional rectum, pelvis, pelvis and para-aortic, axilla, or other); prevalence of lymphatic metastases (<25%, 25%-50%, or >50%; these cut points were chosen a priori to provide a relatively simple interpretation for clinicians); language (German or English); complete vs incomplete outcome verification; and whether reviewers of the index test were blinded to the results of the reference test and vice versa.
We assessed whether the retrieved studies had results that were not representative of the full range of evidence that has been produced (publication bias) by means of a regression test of the natural logarithm of the diagnostic odds ratio on the inverse of the effective sample size (23) . The regression test will be statistically significant if small-study effects cause asymmetry. We present these results as exploratory because this approach is known to be unreliable in datasets with substantial between-study variation and when thresholds favor sensitivity over specificity or vice versa (23, 24) .
Statistical analyses were conducted using STATA 10.0 (StataCorp LP, College Station, TX), notably the midas (25) and metandi (26) commands, MetaDisc (27) , and MIX (28) software. All statistical tests were two-sided, and statistical significance was defined as a P value less than .05.
results
Literature Search and Study Selection
The literature search identified 1089 potentially relevant titles (Figure 1) . We excluded 926 titles because the study investigated an infectious disease or other nonmalignant diseases, the study subjects were not human, or the study examined the technical aspects of the imaging device rather than its diagnostic accuracy. Eighty-one articles were selected for full-text review, and, after cross-checking the reference lists, 31 additional full-text papers were selected. Fifteen of these 31 articles were included in the analyses. The final number of studies considered for inclusion in the meta-analysis was 43 ( Figure 1 ).
Data Extraction and Quality Assessment
Of the 43 studies considered for inclusion in the meta-analysis, 32 studies (3-5,19,29-56) reported patient-level diagnostic data ( Figure 1 and Table 1 ). Eleven studies (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) were not included in the meta-analysis because they reported diagnostic data at the level of the lymph node, anatomic location of the lymph node, side of body (left or right), or tumor (Supplementary We assessed the quality of the 32 studies according to the 13-item QUADAS assessment tool (Figure 2 and Supplementary  Table 2 , available online). Three of the 13 items could be scored in all included articles: completeness of verification via a reference standard of diagnosis (item 5), reporting of uninterpretable results (item 12), and explanation of withdrawals from the study (item 13).
Differential verification bias was present in 35% of the studies. Also, blinding to index and reference test results was poorly reported by 90% and 38% of the studies, respectively, as was the presence of uninterpretable test results (81%). Three other QUADAS items were reported in less than 50% of the included studies, namely the availability of clinical data that would be available in clinical practice when using the index test (25%), the time period between the index test and the reference test (41%), and whether patients received the same reference test regardless of the index test result (47%).
Meta-analysis
The overall sensitivity of all 32 studies estimated from the bivariate model was 0.72 (95% CI = 0.66 to 0.79), and the specificity was 0.87 (95% CI = 0.82 to 0.91). There was substantial heterogeneity across studies for sensitivity (I 2 = 62.4) and specificity (I 2 = 84.2) (Figure 3) .
For the 11 studies that used a single criterion for metastasis, the sensitivity was 0.71 (95% CI = 0.61 to 0.79) and the specificity was 0.88 (95% = 0.80 to 0.93) ( Table 2 ). There was substantially less heterogeneity across these studies for sensitivity (I 2 = 8.4) and specificity (I 2 = 50.3). The area under the summary receiver operating characteristic curve for the 11 studies that used a single malignancy criterion was 0.84 (95% CI = 0.80 to 0.87) (Figure 4) . The estimates of sensitivity and specificity were essentially unchanged for studies that used multiple malignancy criteria without contrast enhancement (0.70 [95% CI = 0.58 to 0.79] and 0.86 [95% CI = 0.68 to 0.94]). For the nine studies that used multiple malignancy criteria with contrast enhancement, the sensitivity increased to 0.84 (95% CI = 0.70 to 0.92) and the specificity was 0.82 (95% CI = 0.72 to 0.89), with substantial heterogeneity across these studies for sensitivity (I 2 = 49.5) and specificity (I 2 = 67.2) ( Table 2 ). The area under the summary receiver operating characteristic curve for these nine studies was 0.90 (95% CI = 0.87 to 0.92) (Figure 4) . Six * NS = not specified. † 1 = studies that used a single malignancy criterion; 2 = studies that used multiple malignancy criteria without using contrast highlighting in their malignancy criteria; 3 = studies that used multiple malignancy criteria with contrast highlighting in their malignancy criteria; -= studies that did not specify the malignancy criterion used.
studies did not present their malignancy criterion and were therefore not included in this subgroup analysis.
Regarding the other covariates, five studies combined paraaortic and pelvic lymph node evaluation, which resulted in a lower estimate for sensitivity than the pooled sensitivity of the five studies that evaluated pelvic lymph nodes only (0.43 [95% CI = 0.30 to 0.57] vs 0.79 [95% CI = 0.67 to 0.88]). The sensitivity of gadolinium-enhanced MRI increased with increasing prevalence of disease, whereas the specificity declined (Table 2 ). In general, the sensitivity of gadolinium-enhanced MRI tended to be higher when no differential or partial verification was present. Germanlanguage studies had higher diagnostic accuracy estimates (sensitivity and specificity) than English-language studies ( Table 2) .
The regression test of the natural logarithm of the diagnostic odds ratio on the inverse of the effective sample size was statistically significant (P = .04). Figure 5 illustrates this test graphically, with the diagnostic odds ratio on the vertical axis and the inverse of the effective sample size on the horizontal axis. An intercept that is statistically significantly different from zero indicates the presence of small-study effects, that is, the tendency that smaller studies have higher diagnostic odds ratios than bigger studies. However, because in a diagnostic setting, there are many explanations other than publication bias for small-study effects, the borderline statistical significance should be interpreted with caution. According to the result of the regression test, however, publication bias cannot be ruled out.
Discussion
In this systematic review and meta-analysis, we investigated the diagnostic accuracy of gadolinium-enhanced MRI for the detection of lymph node metastases. Histopathologic examination of the lymph nodes was used as the reference test. We considered 43 studies for inclusion in the meta-analysis and quantified the pooled sensitivities and specificities of the 32 studies that provided data suitable for the meta-analysis. We found an overall pooled sensitivity of 0.72, with a specificity of 0.87. However, substantial between-study heterogeneity was present, particularly with regard to variation in the type and number of malignancy criteria that were used to stage the lymph nodes. In anticipation of this between-study heterogeneity, we defined a priori three subgroups of studies for analysis: those that used a single malignancy criterion, those that used multiple malignancy criteria (without including contrast enhancement), and those that used multiple malignancy criteria and included contrast enhancement. When multiple malignancy criteria were used together with contrast enhancement (ie, the third subgroup), the sensitivity of contrastenhanced MRI in staging lymph node metastasis was 0.84, with a specificity of 0.82. A previous meta-analysis showed that the use of USPIO particles as a lymphotropic intravenous contrast agent to stage lymphatic metastases increased the diagnostic performance of MRI (6) . However, USPIO administration has some clinical and logistical disadvantages (7) (8) (9) . Another approach for lymph node imaging is positron emission tomography, which evaluates tissue functionality. The major limitation of positron emission tomography is its low spatial resolution. Although newly developed methods for conducting positron emission tomography and computed tomography have increased the resolution to 5 mm, small metastases are still being missed (18) . Gadoliniumenhanced MRI does not have the limitations of either of these modalities. Imaging can be performed directly after gadolinium administration. Furthermore, gadolinium is approved for use in Europe and the United States and is also commonly used for primary tumor visualization, requiring no need to administer additional contrast agents with potentially adverse effects. However, further research is needed to investigate the value of adding gadolinium-enhanced MRI to inexpensive and noninvasive diagnostic approaches.
This study has several limitations. First, we found that there was a considerable lack of reporting of diagnostic study quality items, particularly those involving the blinding of reviewers of the reference test to the index test and vice versa, the availability of clinical data when interpreting the index test, the length of time between the index test and the reference test, and on whether patients received the same reference test regardless of the index test result (QUADAS items 9, 10, 11, 4, and 6, respectively). This lack of reporting of diagnostic study quality items limited the information provided by our quality assessment and prevented us from conducting formal analyses based on the quality assessment items.
Second, for practical reasons, we included only studies that were written in German or English. We therefore may have missed relevant studies that were published in other languages, possibly introducing publication bias. The regression test for publication bias (or rather, for small-study effects) was indeed statistically significant, although this result only indicates that effects in small studies may be different from effects in larger studies. The regression test is sensitive to selective threshold effects that are likely to play a role in diagnostic datasets such as the one used in this study (23) , and we therefore cannot attribute the small-study effects directly to publication-related factors.
Third, there are numerous contrast agents, doses, and administration routes of contrast agents used in MRI. We could not perform separate subgroup analyses because the majority of included studies (at least 27 of the 32 studies, Table 1 ) used gadoliniumdiethylenetriamine penta-acetic acid as an intravenous contrast agent at a dosage of 0.1 mmol/kg body weight. Summary receiver operating characteristic (ROC) curves from the bivariate analysis with 95% confidence region for nine studies that included contrast enhancement in their malignancy criteria and 11 studies that used a single malignancy criterion. Black circles represent studies that included contrast enhancement in their malignancy criteria. The gray circles represent studies that used a single malignancy criterion. The size of the circles indicates the weight of each study (ie, the number of patients included in the study). The black and gray squares represent the mean natural logarithm of the diagnostic odds ratios, and the dotted black and gray lines represent the corresponding 95% confidence intervals. Sensitivity is set on the y-axis, specificity on the x-axis. The solid black and gray lines represent the summary ROC curves. * CI = confidence interval; ND = not done. † Six studies did not specify their malignancy criterion. ‡ Studies including lymph nodes located in the head and neck region or in the mediastinum were not taken into account in this subgroup analysis because no bivariate analysis could be performed on fewer than four studies.
Finally, in the overall analyses of the diagnostic accuracy of gadolinium-enhanced MRI for the detection of lymph node metastases, we pooled the studies irrespective of the primary tumor site, which was the same approach used by Will et al. (6) in a metaanalysis of the diagnostic precision of nanoparticle-enhanced MRI for lymph node metastases. Lymph node metastases derived from primary tumors may, to some extent, differ in their biological properties because of differences in the primary tumors. However, we believed that gadolinium-enhanced imaging of lymph node metastasis is equally effective over all body regions. Because our endpoint was the detection of lymph node metastases rather than evaluation of the primary tumor characteristics, we assumed that the primary tumor was less relevant to the actual performance of gadoliniumenhanced MRI in lymph node staging. Nevertheless, we also performed a subgroup analyses according to the anatomic region in which the harvested lymph nodes were located. Results of several regions were pooled (Table 2 ), and we found that different body regions showed differences with regard to the diagnostic performance of MRI. However, we do not believe that these differences are because of biological properties of the primary tumors but rather to MRI quality aspects (eg, bowel movement disturbs magnetic resonance images more when evaluating regional rectal lymph nodes than when evaluating lymph nodes located in the axilla). Summarizing the diagnostic accuracy across cancer-specific sites was not possible because of the small number of studies per primary tumor.
In conclusion, the results of this meta-analysis suggest that contrast highlighting of lymph nodes should be included as a malignancy criterion when gadolinium contrast agent is used for primary tumor visualization. We further advocate the use of uniform malignancy criteria, including contrast enhancement, for standardization of future evaluations. Gadolinium enhancement by itself does not have the diagnostic accuracy to replace histopathologic examination of lymph nodes; however, it can help identify suspicious lymph nodes that should be surgically collected for histopathologic examination.
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